Abstract: AIM: To investigate the combined effects of fuvastatin and felodipine on blood pressure, hs-CRP and vascular endothelial function in hypertensive patients with impaired glucose tolerance (IGT). METHODS: One hundred and twenty seven patients with impaired glucose tolerance were randomized into two groups: treatment group and control group. Serum levels of soluble intercellular adhesion molecule-1 (sICAM-1), soluble vascular cell adhesion molecule-1 (sVCAM-1) and C-reactive protein (CRP) were measured before and after treatment. RESULTS: Twelve weeks after therapy, CRP levels ［control group: (2.9±1.5) mg/L vs.(2.4±0.7) mg/L, P<0.05; treatment group: (2.9±1.5) mg/L vs.(1.3±0.4) mg/L, P<0.01］, sICAM-1 ［control group: (114 ± 47) μg/L vs.( 98±28) μg/L, P<0.05; treatment group: (118±46) μg/L vs.(78±24) μg/L, P<0.01］ and sVCAM-1 ［control group: (226±99) μg/L vs.(190±56) μg/L, P<0.05; treatment group: (230±97) μg/L vs.(158±36) μg/L, P<0.01］ in the two groups significantly decreased. Compared with levels in the control group, the CRP levels ［(2.4±0.7)mg/L vs.(1.3±0.4)mg/L, P<0.05］; sICAM-1 ［(98±28)μg/L vs.(78±24)μg/L, P<0.05］ and sVCAM-1 ［(190±56)μg/L vs.(158±36)μg/L, P<0.05］ in the treatment group significantly decreased. CONCLUSION: Combination of fuvastatin and felodipine improves vascular endothelial-dependent diastolic function in hypertensive patients with impaired glucose tolerance by reducing plasma hs-CRP and blood glucose.